Krishnansu Tewari, MD

Closing their conversation, Ramez Eskander, MD, and Krishnansu Tewari, MD, share how they envision the future treatment landscape for patients with advanced endometrial cancer.

Key opinion leaders discuss targeted treatment regimens for advanced or recurrent endometrial cancer that are currently under development.

Krishnansu Tewari, MD, presents the profile of a 68-year-old postmenopausal woman with recurrent endometrial cancer for discussion.

Experts explain how they change their treatment strategies if a patient with advanced endometrial cancer does not respond to treatment or experiences disease progression.

Krishnansu Tewari, MD, reviews emerging data from two studies investigating immunotherapy-based combination regimens for the first-line treatment of advanced endometrial cancer.

Krishnansu Tewari, MD, details the first-line treatment options for patients with recurrent endometrial cancer.

Ramez Eskander, MD, presents the profile of a 64-year-old postmenopausal woman diagnosed with recurrent endometrial carcinoma for discussion.

Ramez Eskander, MD, and Krishnansu Tewari, MD, provide an overview of endometrial cancer, including prevalence, staging criteria, and molecular profiling.

A discussion on the best way to sequence therapies for patients with MSI-high and MMR-proficient endometrial carcinoma.

Oncologists debate the proper treatment of a patient with a grade 2 endometrial carcinoma tumor.

Dr David O’Malley explains when to add and remove trastuzumab during endometrial carcinoma therapy.

A review of data from several clinical trials on the use of I/O + chemotherapy as treatment for endometrial carcinoma.

Experts explain the need for germline testing and genetic counseling for patients with endometrial carcinoma as demonstrated by a patient case.

Drs Bradley Monk and David O’Malley explain dose reduction in endometrial carcinoma treatment based on clinical trial data.

Physician-researchers discuss the risk of recurrence in endometrial carcinoma and the available treatment options after relapse.

An overview of biomarker testing in endometrial carcinoma.

Oncologists describe a typical presentation of endometrial carcinoma and debate the implications of radiation treatment.

Experts take a closer look at the data points from KEYNOTE-826 to consider pembrolizumab’s potential role in metastatic cervical cancer management.

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses the trial design with cemiplimab (Libtayo) in recurrent or metastatic cervical cancer.

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses immunotherapeutic strategies in cervical cancer.

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses the evolution of treatment in cervical cancer.

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses the promise of immunotherapy in cervical cancer.

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses the GOG 3016/ENGOT-cx9 trial in patients with recurrent or metastatic cervical cancer.